CN1895237A - 和厚朴酚脂质体冻干粉制剂及其在制备治疗恶性肿瘤药物中的应用 - Google Patents
和厚朴酚脂质体冻干粉制剂及其在制备治疗恶性肿瘤药物中的应用 Download PDFInfo
- Publication number
- CN1895237A CN1895237A CN 200610021277 CN200610021277A CN1895237A CN 1895237 A CN1895237 A CN 1895237A CN 200610021277 CN200610021277 CN 200610021277 CN 200610021277 A CN200610021277 A CN 200610021277A CN 1895237 A CN1895237 A CN 1895237A
- Authority
- CN
- China
- Prior art keywords
- honokiol
- group
- liposome
- tumor
- polyethylene glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 44
- 239000000843 powder Substances 0.000 title claims abstract description 35
- -1 phenol lipid Chemical class 0.000 title claims description 53
- 238000002360 preparation method Methods 0.000 title claims description 51
- 229940079593 drug Drugs 0.000 title abstract description 17
- 206010028980 Neoplasm Diseases 0.000 title description 71
- 241000218378 Magnolia Species 0.000 title 1
- VVOAZFWZEDHOOU-UHFFFAOYSA-N honokiol Natural products OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 claims abstract description 199
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 claims abstract description 185
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 claims abstract description 156
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 39
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 32
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 16
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 15
- 239000000787 lecithin Substances 0.000 claims abstract description 15
- 235000010445 lecithin Nutrition 0.000 claims abstract description 15
- 229940067606 lecithin Drugs 0.000 claims abstract description 15
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 13
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 12
- 238000011282 treatment Methods 0.000 claims description 68
- 238000001959 radiotherapy Methods 0.000 claims description 38
- 229930012538 Paclitaxel Natural products 0.000 claims description 25
- 229960001592 paclitaxel Drugs 0.000 claims description 25
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 25
- 239000004698 Polyethylene Substances 0.000 claims description 22
- 229920000573 polyethylene Polymers 0.000 claims description 22
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 claims description 20
- 229930195573 Amycin Natural products 0.000 claims description 20
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 20
- 229960004316 cisplatin Drugs 0.000 claims description 20
- 229920001223 polyethylene glycol Polymers 0.000 claims description 17
- 239000002202 Polyethylene glycol Substances 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 16
- 201000008275 breast carcinoma Diseases 0.000 claims description 7
- 239000002502 liposome Substances 0.000 abstract description 101
- 201000005202 lung cancer Diseases 0.000 abstract description 18
- 208000020816 lung neoplasm Diseases 0.000 abstract description 18
- 230000001235 sensitizing effect Effects 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 description 58
- 241000699670 Mus sp. Species 0.000 description 53
- 210000001519 tissue Anatomy 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 34
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 29
- 238000002512 chemotherapy Methods 0.000 description 20
- 230000003203 everyday effect Effects 0.000 description 20
- 210000004881 tumor cell Anatomy 0.000 description 20
- 239000007924 injection Substances 0.000 description 19
- 238000002347 injection Methods 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 238000007912 intraperitoneal administration Methods 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 230000004083 survival effect Effects 0.000 description 13
- 230000004614 tumor growth Effects 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 230000006907 apoptotic process Effects 0.000 description 11
- 238000004043 dyeing Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 238000011125 single therapy Methods 0.000 description 8
- 230000003442 weekly effect Effects 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 206010028851 Necrosis Diseases 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000017074 necrotic cell death Effects 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000011740 C57BL/6 mouse Methods 0.000 description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 5
- 229930003268 Vitamin C Natural products 0.000 description 5
- 210000004088 microvessel Anatomy 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 235000019154 vitamin C Nutrition 0.000 description 5
- 239000011718 vitamin C Substances 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical group OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 239000000890 drug combination Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000011261 inert gas Substances 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000011017 operating method Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000010409 thin film Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100028999 High mobility group protein HMGI-C Human genes 0.000 description 2
- 101000986379 Homo sapiens High mobility group protein HMGI-C Proteins 0.000 description 2
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 239000000823 artificial membrane Substances 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000001132 ultrasonic dispersion Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000008636 Neoplastic Processes Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 208000030270 breast disease Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000002468 fat body Anatomy 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229940028435 intralipid Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940087400 lecithin 50 mg Drugs 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
时间(min) | 3 | 5 | 10 | 15 | 30 | 45 | 60 | 120 | 240 | 480 | |
和厚朴酚脂质体冻干粉制剂 | C(ug/ml) | 9.714 | 7.154 | 4.953 | 3.810 | 1.887 | 0.998 | 0.687 | 0.373 | 0.607 | 0.624 |
InC | 2.274 | 1.968 | 1.600 | 1.338 | 0.635 | 0.077 | -0.299 | -0.684 | -0.700 | -0.700 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006100212778A CN1895237B (zh) | 2006-06-27 | 2006-06-27 | 和厚朴酚脂质体冻干粉制剂及其在制备治疗恶性肿瘤药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006100212778A CN1895237B (zh) | 2006-06-27 | 2006-06-27 | 和厚朴酚脂质体冻干粉制剂及其在制备治疗恶性肿瘤药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1895237A true CN1895237A (zh) | 2007-01-17 |
CN1895237B CN1895237B (zh) | 2011-05-11 |
Family
ID=37607974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006100212778A Active CN1895237B (zh) | 2006-06-27 | 2006-06-27 | 和厚朴酚脂质体冻干粉制剂及其在制备治疗恶性肿瘤药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1895237B (zh) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008074896A1 (en) * | 2006-12-21 | 2008-06-26 | Prendergast Patrick T | Compositions and methods for treatment of chronic neurological disorders |
CN102178666A (zh) * | 2011-03-21 | 2011-09-14 | 四川大学 | 和厚朴酚在制备预防或治疗颅内占位性病变和颅内组织器官炎症的药物中的用途 |
CN102228452A (zh) * | 2011-05-06 | 2011-11-02 | 郑州大学 | 一种和厚朴酚或厚朴酚或二者的混合物固体脂质纳米粒制剂及其制备方法 |
CN102302451A (zh) * | 2011-09-13 | 2012-01-04 | 郑州大学 | 一种和厚朴酚亚微乳注射剂及其生产方法 |
CN104622880A (zh) * | 2015-02-09 | 2015-05-20 | 南京医科大学第一附属医院 | 一种抗肿瘤药物组合物 |
CN105456194A (zh) * | 2015-12-16 | 2016-04-06 | 成都理工大学 | 厚朴酚脂质体及其衍生制剂和制备方法 |
CN107998079A (zh) * | 2017-11-10 | 2018-05-08 | 湖北大学 | 一种厚朴总酚长循环脂质体冻干口服制剂及其制备方法 |
CN112778098A (zh) * | 2020-12-31 | 2021-05-11 | 成都金瑞基业生物科技有限公司 | 和厚朴酚晶型、无定形及其制备方法 |
CN115252589A (zh) * | 2020-09-27 | 2022-11-01 | 成都金瑞基业生物科技有限公司 | 和厚朴酚的医药用途 |
CN116270473A (zh) * | 2023-05-25 | 2023-06-23 | 成都金瑞基业生物科技有限公司 | 一种共载脂质体及其制备方法 |
US12030841B2 (en) | 2020-12-31 | 2024-07-09 | Chengdu Jinrui Foundation Biotech Co., Ltd. | Honokiol crystal forms, amorphous form and preparation thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1511517A (zh) * | 2002-12-30 | 2004-07-14 | 北京大学第一医院 | 厚朴酚与和厚朴酚及其衍生物在抑制血管生成中的应用 |
-
2006
- 2006-06-27 CN CN2006100212778A patent/CN1895237B/zh active Active
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008074896A1 (en) * | 2006-12-21 | 2008-06-26 | Prendergast Patrick T | Compositions and methods for treatment of chronic neurological disorders |
CN102178666A (zh) * | 2011-03-21 | 2011-09-14 | 四川大学 | 和厚朴酚在制备预防或治疗颅内占位性病变和颅内组织器官炎症的药物中的用途 |
CN102228452A (zh) * | 2011-05-06 | 2011-11-02 | 郑州大学 | 一种和厚朴酚或厚朴酚或二者的混合物固体脂质纳米粒制剂及其制备方法 |
CN102228452B (zh) * | 2011-05-06 | 2012-09-26 | 郑州大学 | 一种和厚朴酚或厚朴酚或二者的混合物固体脂质纳米粒制剂及其制备方法 |
CN102302451A (zh) * | 2011-09-13 | 2012-01-04 | 郑州大学 | 一种和厚朴酚亚微乳注射剂及其生产方法 |
CN102302451B (zh) * | 2011-09-13 | 2012-10-03 | 郑州大学 | 一种和厚朴酚亚微乳注射剂及其生产方法 |
CN104622880B (zh) * | 2015-02-09 | 2017-05-17 | 南京医科大学第一附属医院 | 一种抗肿瘤药物组合物 |
CN104622880A (zh) * | 2015-02-09 | 2015-05-20 | 南京医科大学第一附属医院 | 一种抗肿瘤药物组合物 |
CN105456194A (zh) * | 2015-12-16 | 2016-04-06 | 成都理工大学 | 厚朴酚脂质体及其衍生制剂和制备方法 |
CN107998079A (zh) * | 2017-11-10 | 2018-05-08 | 湖北大学 | 一种厚朴总酚长循环脂质体冻干口服制剂及其制备方法 |
CN115252589A (zh) * | 2020-09-27 | 2022-11-01 | 成都金瑞基业生物科技有限公司 | 和厚朴酚的医药用途 |
CN112778098A (zh) * | 2020-12-31 | 2021-05-11 | 成都金瑞基业生物科技有限公司 | 和厚朴酚晶型、无定形及其制备方法 |
WO2022141684A1 (zh) * | 2020-12-31 | 2022-07-07 | 成都金瑞基业生物科技有限公司 | 和厚朴酚晶型、无定形及其制备方法 |
US12030841B2 (en) | 2020-12-31 | 2024-07-09 | Chengdu Jinrui Foundation Biotech Co., Ltd. | Honokiol crystal forms, amorphous form and preparation thereof |
CN116270473A (zh) * | 2023-05-25 | 2023-06-23 | 成都金瑞基业生物科技有限公司 | 一种共载脂质体及其制备方法 |
CN116270473B (zh) * | 2023-05-25 | 2023-12-19 | 成都金瑞基业生物科技有限公司 | 一种共载脂质体及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1895237B (zh) | 2011-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1895237A (zh) | 和厚朴酚脂质体冻干粉制剂及其在制备治疗恶性肿瘤药物中的应用 | |
CN108837154B (zh) | 一种细胞膜仿生脂蛋白靶向纳米递药系统的制备及应用 | |
CN104353075B (zh) | 一种水溶性磁性二氧化钛及其制备方法与应用 | |
Sun et al. | An enzyme-responsive and transformable PD-L1 blocking peptide-photosensitizer conjugate enables efficient photothermal immunotherapy for breast cancer | |
Ma et al. | SM5-1-conjugated PLA nanoparticles loaded with 5-fluorouracil for targeted hepatocellular carcinoma imaging and therapy | |
CN110101684A (zh) | 一种生物正交靶向的细胞膜仿生纳米颗粒及其制备方法和用途 | |
Shi et al. | Biofilm-encapsulated nano drug delivery system for the treatment of colon cancer | |
CN1842322A (zh) | 用于光动力疗法的非极性光敏剂制剂 | |
CN105796510B (zh) | 肿瘤靶向的药剂及其制备方法和应用 | |
CN111888336B (zh) | 碳酸钙聚(乳酸-羟基乙酸)复合物微粒及其制备和应用 | |
CN1931156A (zh) | 紫杉醇类物质固体脂质纳米粒及其制备方法 | |
CN105288646A (zh) | 一种光敏剂磷脂化合物、其药物组合物及应用 | |
CN115414390B (zh) | 具有改善肠道微生态性能和增强肿瘤免疫检查点抑制剂治疗效果的益生菌复合制剂及应用 | |
CN1813677A (zh) | 槲皮素长效脂质体粉针剂及其制备方法 | |
CN114504656A (zh) | 一种细菌介导的纳米药物递送系统及其制备方法和应用 | |
CN110314230A (zh) | 具有靶向性的聚多巴胺包覆普鲁士蓝纳米复合材料及其制备方法 | |
CN114288278B (zh) | 一种载药微藻、制备方法及其应用 | |
Xin et al. | Algae: A robust living material against cancer | |
Sun et al. | Charge-reversal biodegradable nanoplatform with ferroptosis and ICD induction for tumor synergistic treatment | |
CN106606783B (zh) | 一种靶向共递释光敏剂与化疗药物的药物递释系统 | |
CN1895220A (zh) | 20(R)-人参皂苷Rg3药用水溶性中间体及制备方法 | |
CN1274366C (zh) | 药用纳米碳球及其在制备治疗癌症药物中的应用 | |
CN110292565B (zh) | 不透过血脑屏障的脂质体复合物及其制备方法 | |
CN1316972C (zh) | 一种抗癌止痛制剂 | |
CN1278676C (zh) | 姜黄素注射制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Wei Yuquan Inventor after: Chen Lijuan Inventor before: Wei Yuquan Inventor before: Chen Lijuan Inventor before: Fan Linyu |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: WEI YUQUAN CHEN LIJUAN FAN LINYU TO: WEI YUQUAN CHEN LIJUAN |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HENGDU JINRUI JIYE BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: SICHUAN UNIVERSITY Effective date: 20140722 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 610041 CHENGDU, SICHUAN PROVINCE TO: 610000 CHENGDU, SICHUAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140722 Address after: 610000 Sichuan city in Chengdu Province, Wuhou District Road No. 142 of 17 Shaoling Street No. 1 building Patentee after: Chengdu Jinrui Jiye Bio-Technology Co.,Ltd. Address before: 610041 State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, Chengdu, Sichuan Province Patentee before: Sichuan University |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Magnolol liposome lyophilized powder preparation and its application in the preparation of drugs for the treatment of malignant tumors Effective date of registration: 20211209 Granted publication date: 20110511 Pledgee: Bank of Chengdu science and technology branch of Limited by Share Ltd. Pledgor: Chengdu Jinrui Jiye Bio-Technology Co.,Ltd. Registration number: Y2021510000293 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |